Leuven

reMYND and the US NINDS Epilepsy Therapy Screening Program (ETSP) begin collaboration on epilepsy program

Retrieved on: 
Thursday, November 4, 2021
Death, Central nervous system disease, Quality of life, University, Lists of diseases, Disease, Survival, CNS, NV, Drug design, Patient, NINDS, Insulin, FDA, Neuroprotection, Management of drug-resistant epilepsy, Dravet syndrome, Gene therapy for epilepsy, KU, CD3, Cognition, CRO, Program, Diabetes, Pharmacokinetics, Degenerative disease, Epilepsy, Hospital, Central nervous system, Contract research organization, Catholic University of Leuven (1834–1968), Â, Pharmaceutical industry

The ReS3-T program is the result of a collaboration with KU Leuvens Centre for Drug Design and Discovery (CD3).

Key Points: 
  • The ReS3-T program is the result of a collaboration with KU Leuvens Centre for Drug Design and Discovery (CD3).
  • The program offers screening of treatment compounds, with a focus on therapy-resistant epilepsies, disease prevention and modification and performs testing with high scientific rigor.
  • reMYND is a clinical stage company developing novel treatments for Alzheimers, diabetes, epilepsy and other diseases caused by cellular dysfunction.
  • reMYND was founded in 2002 as a spin-off from the University of Leuven, and has been substantially supported by grants from VLAIO/IWT (Flanders, Belgium).

reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase

Retrieved on: 
Thursday, October 21, 2021
UNLV, Safety, SAD, MAD, Phase, Central nervous system disease, Volunteering, University, Disease, Human, CNS, NV, Patient, Insulin, Medical University of Vienna, Calcium, Learning, Food, Cognition, CRO, Clinical trial, Pharmacokinetics, Diabetes, Degenerative disease, Central nervous system, Contract research organization, Faculty of Theology, Old University of Leuven, Amnesia, Medical school, Pharmaceutical industry

The multiple-ascending dose (MAD) phase has been initiated well before the maximum tolerable dose has been reached.

Key Points: 
  • The multiple-ascending dose (MAD) phase has been initiated well before the maximum tolerable dose has been reached.
  • To date, healthy volunteers in the SAD phase have been dosed up to 700 mg, and food impact has been assessed at this high dose.
  • The preclinical studies and early clinical trials of ReS19-T provide a strong foundation for advancing this innovative treatment.
  • With this promising data we are getting close to a pivotal test of the calcium hypothesis in patients in 2022.

Materialise Announces Pricing of Public Offering of 4.0 Million American Depositary Shares (ADSs)

Retrieved on: 
Thursday, June 10, 2021
U.S. Securities and Exchange Commission, Stock market, Shelf registration, Forward-looking statement, Security, Registration statement, Financial economics, Investment, Market economics), SEC filings

The offering is expected to close onJune 14, 2021, subject to the satisfaction of customary closing conditions.

Key Points: 
  • The offering is expected to close onJune 14, 2021, subject to the satisfaction of customary closing conditions.
  • The securities described above are being offered by Materialise pursuant to a shelf registration statement on Form F-3 (No.
  • 333-226006) previously filed by Materialise with theSecurities and Exchange Commission(the SEC) and declared effective onJuly 6, 2018.
  • Materialise disclaims any obligation to update these forward-looking statements because of new information, future events or circumstances or other factors.

AB InBev 100+ Accelerator partners with The Coca-Cola Company, Colgate-Palmolive and Unilever for Sustainable Startup Innovation

Retrieved on: 
Thursday, April 22, 2021

Sustainable business is smart business, and we are working to solve huge problems that no one company can handle alone.

Key Points: 
  • Sustainable business is smart business, and we are working to solve huge problems that no one company can handle alone.
  • \xe2\x80\x9cWe are committed to working with partners including innovators to bring more sustainable solutions to market by leveraging our size and scale.
  • We are pleased to be a partner of the 100+ Accelerator.\xe2\x80\x9d\nThe 100+ Accelerator\xe2\x80\x99s startup innovations have already created tremendous impact.
  • \xe2\x80\x9cAnd we know that we can achieve our purpose faster and more effectively with equally committed partners like AB InBev, Coca-Cola and Unilever.

Materialise Acquires Option to Buy Link3D

Retrieved on: 
Tuesday, April 13, 2021

b'Leuven (Belgium), April 13, 2021 (GLOBE NEWSWIRE) -- Materialise, a global leader in 3D printing solutions, has acquired an option to buy Link3D Inc., an additive workflow and manufacturing execution systems (MES) company.

Key Points: 
  • b'Leuven (Belgium), April 13, 2021 (GLOBE NEWSWIRE) -- Materialise, a global leader in 3D printing solutions, has acquired an option to buy Link3D Inc., an additive workflow and manufacturing execution systems (MES) company.
  • In addition, the acquisition will allow Materialise to accelerate its roadmap to offer cloud-based access to its integrated software platform.
  • Materialise and Link3D each offer MES-solutions that help these organizations gain control over their manufacturing floor.
  • Materialise expects to exercise the option before the end of the year.\nMaterialise incorporates three decades of 3D printing experience into a range of software solutions and 3D printing services, which together form the backbone of the 3D printing industry.

reMYND extends Series B funding to EUR 24 million

Retrieved on: 
Thursday, January 21, 2021
Financial services, Banks, Finance, ABN AMRO, Fortis, CAC 40, BNP Paribas, Disease

Leuven Belgium, 21 January 2021: reMYND NV, a clinical stage company developing innovative treatments for Alzheimers, diabetes and other diseases caused by cellular dysfunction, has successfully extended its Series B financing round to EUR 24 million.

Key Points: 
  • Leuven Belgium, 21 January 2021: reMYND NV, a clinical stage company developing innovative treatments for Alzheimers, diabetes and other diseases caused by cellular dysfunction, has successfully extended its Series B financing round to EUR 24 million.
  • The second close of EUR 12 million by a consortium of investors including Korys Investments, FPIM, KU Leuven, PMV, and BNP Paribas Fortis Private Equity follows an initial EUR 12 million raised in December 2018.
  • Staph Leavenworth Bakali, Chairman of reMYND, commented This successful financing round comes at an exciting time in reMYNDs growth story.
  • reMYND is a clinical stage company developing novel treatments for Alzheimers, diabetes and other diseases caused by cellular dysfunction.

reMYND commences first-in-human trial of ReS19-T Alzheimer’s program

Retrieved on: 
Thursday, December 3, 2020
Branches of biology, Abnormal psychology, Alzheimer's disease, Dementia, Psychiatric diagnosis, Neuroscience, Psychiatry

reMYND has a broader pipeline of novel programs in development, with a diabetes program scheduled to begin in-human trials in mid-2021.

Key Points: 
  • reMYND has a broader pipeline of novel programs in development, with a diabetes program scheduled to begin in-human trials in mid-2021.
  • The reMYND team has been meticulous in their research, focussing on fundamental cellular processes related to neurodegeneration in Alzheimers, resulting in this novel and differentiated approach.
  • reMYND is a clinical stage company developing treatments for Alzheimers, diabetes and other diseases caused by cellular dysfunction.
  • reMYNDs most advanced program is ReS19-T, an investigational compound for the treatment of Alzheimers, which entered the clinic in Q4 2020.

Materialise Introduces Build Processor Support for Desktop Metal Binder Jetting Systems

Retrieved on: 
Tuesday, November 10, 2020
Business, Articles, Industrial processes, 3D printing, Desktop Metal, Metalworking, Jetting, Sintering, ATI Technologies, Powder bed and inkjet head 3D printing, Materialise NV

Leuven, Belgium, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Materialise today announced support for Desktop Metal Binder Jetting technologies, including Desktop Metals Shop System and Production System platforms.

Key Points: 
  • Leuven, Belgium, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Materialise today announced support for Desktop Metal Binder Jetting technologies, including Desktop Metals Shop System and Production System platforms.
  • The partnership includes the introduction of a Desktop Metal Build Processor to support metal Binder Jetting technology for the companys Shop System and Production System technologies.
  • Materialise Build Processors are widely used in industrial printing, translating 3D designs into machine-specific build files for a variety of machines.
  • As part of the announcement, Materialise has also introduced sintering support generation for metal Binder Jetting as part of Magics SG+ module and metal Binder Jetting enhanced 3D nesting.

MaterialiseObtains CE Marking Certification for Multiple Personalized Medical Devices

Retrieved on: 
Tuesday, November 10, 2020
Medical device, CE marking, Medical Devices Directive, Technology, Medicine, Science and technology, Medical devices

TheCE Marking approvalindicates that amedical device meetsthe requirements of the European Medical Devices Directive.Until now, Materialises personalized devices made use of the custom-made procedure, which requires a medical prescription for every device.

Key Points: 
  • TheCE Marking approvalindicates that amedical device meetsthe requirements of the European Medical Devices Directive.Until now, Materialises personalized devices made use of the custom-made procedure, which requires a medical prescription for every device.
  • When the European Medical Devices Directive came to place in 1993, the use of personalized devices was exceptional.
  • This CE marking certification demonstrates that these personalized devices meet the same stringent quality requirements as regular devices, despitethe challengesinvolvedto make every device match the specific patients anatomy, says Brigitte de Vet, Vice Presidentand Managing DirectorofMaterialiseMedical.
  • The company believes this kind of certification will help raisetheindustry bar toensure patient safety and transparency on personalized devices' production.

Materialise to Accelerate Digital Transformation in the Footcare Industry

Retrieved on: 
Thursday, October 29, 2020
Articles, Computing, Digital transformation, Information society, Information technology, Social change, Personalization, Information

By bringing the RS Print and RSscan technology under one roof, Materialise intends to accelerate its R&D and product development efforts for the personalization of footcare and to build a more comprehensive suite of solutions for footcare experts and their patients.

Key Points: 
  • By bringing the RS Print and RSscan technology under one roof, Materialise intends to accelerate its R&D and product development efforts for the personalization of footcare and to build a more comprehensive suite of solutions for footcare experts and their patients.
  • Through the acquisition, Materialise welcomes an experienced research and development team conducting advanced research in foot measurement, analysis and corrections.
  • In addition to the acquisition, Materialise also announced a strengthening of its strategic partnership with Superfeet through a new collaboration.
  • The partnership builds on Superfeets reputation and marketing network in the insole market, in particular in North America, with a view to accelerating the digital transformation of the footcare industry.